PYROJAS CORPORATION HiTE-T™ Lentiviral Transduction Enhancer for Primary CD3+ T Cells, 10 mg ~200 Reactions, CAR-T TCR-T TIL Cell Therapy Reagent, Self-Inactivating TFP Peptide, Polybrene LentiBOOST RetroNectin Alternative, Spinoculation-Free, GMP-Compatible, RUO

Supplier:  PYROJAS CORPORATION HITET10MG

HiTE-T™ is a high-efficiency lentiviral transduction enhancer engineered for primary human CD3⁺ T cells across CAR-T, TCR-T, TIL, and adoptive cell therapy workflows. As a bi-functional Transient Fusion-Promoting Peptide (TFP), HiTE™ enhances viral entry through dual binding of lentiviral envelope proteins and target cell membranes, then self-inactivates within hours to preserve viability, expansion, exhaustion profiles, and effector function. A high-performing alternative to polybrene (hexadimethrine bromide), LentiBOOST, RetroNectin coating, and spinoculation protocols, HiTE-T™ delivers up to 63% transduction efficiency (3–7× vs. standards), 1.3× better viability, and VCN below the FDA guideline of 5—supporting IND-enabling and clinical translation programs.Applications: CAR-T, TCR-T, TIL, gene editing (CRISPR/Cas9, base editors), reporter studies (GFP, mCherry, luciferase).Specs: 10 mg (~200 rxn); 10× (400 μM) stock; CD4⁺/CD8⁺; −80°C; RUO; PyrOjas Corp.

Catalog No. NC3972843